CemiplimAb Survivorship Epidemiology

Status Active, not recruiting

Clinical Trial Summary

The objectives of the study are: - To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic [nodal or distant]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (defined as locally advanced or metastatic [nodal or distant]) basal cell carcinoma (BCC) in real-world clinical settings - To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (TSARs) in patients with advanced CSCC and patients with advanced BCC receiving cemiplimab treatment in real world clinical settings - To describe patient experience, including patient reported quality of life (QOL) and functional status, and clinician reported performance status in a real-world setting for patients with advanced CSCC and patients with advanced BCC - To describe baseline characteristics that could potentially be associated with health-related outcomes for patients with advanced CSCC and patients with advanced BCC undergoing treatment with cemiplimab - To describe patients who receive cemiplimab as treatment for CSCC or BCC in a real-world setting - To describe real-world use patterns of cemiplimab for CSCC and BCC - To investigate the long-term effects and effectiveness of cemiplimab in patients with advanced CSCC or advanced BCC - To describe the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with advanced CSCC or advanced BCC, regardless of etiology, per available data - To describe the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC per available data - To describe the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with advanced CSCC, regardless of etiology, per available data - To describe the effectiveness of cemiplimab in patients with advanced BCC based on treatment patterns (reason for discontinuation, treatment exposure, etc) of prior Hedgehog inhibitor (HHI) usage

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Basal Cell Carcinoma
Carcinoma
Carcinoma, Basal Cell
Cutaneous Squamous Cell Carcinoma

Clinical Trial Details

NCT number	NCT03836105
Study type	Observational
Source	Regeneron Pharmaceuticals
Contact
Status	Active, not recruiting
Phase
Start date	June 27, 2019
Completion date	October 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Completed	`NCT04229277` - Fast Track Diagnosis of Skin Cancer by Advanced Imaging	N/A
Completed	`NCT05608902` - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed	`NCT05077033` - Intratumoral phIL12 GET	Phase 1
Active, not recruiting	`NCT04928222` - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)	Phase 1/Phase 2
Recruiting	`NCT04929535` - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment	Phase 2
Completed	`NCT02662244` - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma	N/A
Completed	`NCT00959647` - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study	Phase 2
Completed	`NCT00793169` - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed	`NCT00586040` - Photochemical Tissue Bonding	Phase 2
Completed	`NCT00473343` - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma	Phase 3
Active, not recruiting	`NCT06024629` - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting	`NCT05324202` - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management	N/A
Withdrawn	`NCT04099446` - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Completed	`NCT01208831` - An East Asian Study of LDE225	Phase 1
Completed	`NCT01260987` - Fractional CO2 Laser Assisted Photodynamic Therapy	Phase 2/Phase 3
Completed	`NCT01201915` - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma	Phase 2
Completed	`NCT01014819` - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions	N/A
Completed	`NCT00472043` - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CemiplimAb Survivorship Epidemiology — CASE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms